Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nutanix Inc (NTNX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nutanix Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Nutanix Inc trades at $54.79 (market cap $14.81B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.7× Nutanix Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NTNX | |
|---|---|---|
Market Cap | $39.89B | $14.81B |
Sector | Health | Technology |
52-Week High | $491.22 | $81.12 |
52-Week Low | $278.09 | $34.41 |
Enterprise Value | $38.15B | $14.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Nutanix (NTNX) trades at $54.79, down 1.33% on the day, with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals, with Q1 2026 EPS of $0.47 beating expectations and a robust gross profit margin of 87.09%. Recent news highlights momentum, including NVIDIA certification for its storage solution and positive analyst coverage.
The outlook is positive, driven by consistent earnings beats, expanding AI infrastructure opportunities, and a consensus price target of $57.80. Key risks include high valuation multiples and competitive pressures in the hybrid cloud market. Wall Street sentiment is bullish, with 62.5% of analysts rating the stock a Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
